Summary

Bioanalytical Technologies' mission is to support the IBRI's research areas by helping to innovate the next generation of bioanalytical systems and methods. These efforts support and help enable the IBRI's development of new standards of patient care and therapeutics.

Dr. Michael Pugia is leading the development of state-of-the art technology platforms and methods for bioanalytical applications in life sciences. These tools make it possible to measure the most basic elements of cell biology and solve today’s problems in biomolecular analysis with detection limits far lower than current methods. This enables far greater clarity for studying the complexity of biological systems.

Lab Team

Anna Geisinger

Anna Geisinger

Research Associate, Bioanalytical Technologies

Anna Geisinger

Anna Geisinger

Research Associate, Bioanalytical Technologies

Anna Geisinger is a research associate in the IBRI’s Bioanalytical Technologies group. Bioanalytical Technologies supports all of the IBRI’s research centers by helping to innovate the next generation of bioanalytical systems and methods. In her role, Anna is responsible for cell and bacteria culture, assay validation and protocol development, and molecular analysis.

Anna joined the IBRI in November of 2017 as a research analyst in the IBRI’s Single Cell Analytics Center (SCAC), which developed a technology platform to ultimately achieve the diagnosis of infections and diseases from a single cell. With the efforts to commercialize the platform externally, in May 2019, the SCAC transitioned to the internal Bioanalytical Technologies support group.

From 2016 to before joining the IBRI, Anna served as a microbiologist with the Indiana State Department of Health Laboratories. She was responsible for assay development and testing, clinical testing, and outbreak monitoring. From 2011 to 2016, she served as a contractor research associate at then Dow AgroSciences (now Corteva Agriscience) responsible for nucleic acid and protein isolation, molecular analysis, and high-throughput experience associated with DNA isolation and analysis.

Anna earned her B.S. in biology from Indiana University in Bloomington, Ind., with minors in chemistry and Spanish. While at IU, she also served as an undergraduate teaching assistant in the biology department.

Michael Pugia

Michael Pugia, PhD

Investigator and Director, Bioanalytical Technologies

Michael Pugia

Michael Pugia, PhD

Investigator and Director, Bioanalytical Technologies

Michael Pugia, PhD, is an Investigator and Director of the Indiana Biosciences Research Institute's (IBRI) Bioanalytical Technologies group, effective May 2019. Before that, he served as Director of the IBRI’s Single Cell Analytics Center leading the efforts to develop new single-cell bioanalytical technology for measuring proteomic biomarkers as targeted diagnostics for the fields of endocrinology, oncology and infectious disease.

Prior to joining the IBRI, Michael spent 30 years in the biomedical in-vitro diagnostic industry for the Bayer and then Siemens diagnostic divisions. In his roles at Bayer and Siemens he contributed to 21 new product launches that have since produced more than 25 billion test results worldwide. Some of the products also helped to establish new, cost effective healthcare programs, such as Japan’s use of microalbumin/creatinine ratio for annual mass screening of all children for kidney disease.

He spent 15 of those 30 years as a director of research and development working on new systems and methods for point of care (POC) diagnostics and hospital laboratories. Additionally, he spent 20 years leading next generation analytical and diagnostic technology research teams in collaboration with leading design house, health care institutions, universities and technology companies around the world. In his last eight years, he served as a principle key expert for Siemens’ Healthcare sector in Strategic Innovations and lead the Siemens’ contribution to the EU IMI CANCER ID program by placing the Circulating Tumor Cell platform into leading EU cancer centers and the U.S. Siemens CLIA lab for clinical research use.

For his entire career, Michael’s primary biochemistry research interest for clinical diagnostics has been identifying immunity markers for infections in diabetes and co-morbidities.

In 2009, Michael was honored with the Siemens Inventor of the Year award for his pioneering work on the miniaturization of “lab-on-a-chip” diagnostic tools for POC testing. He also was recognized with nine Bayer Science and Technology Awards including the Outstanding Bayer Technology Award, the Bayer Corporate Quality Excellence Award and the Near Patient Testing Segment General Manager Award for Exceptional Leadership for his contributions to the CLINITEK and MULTISTIX urinalysis product lines. 

The American Association of Clinical Chemistry celebrated him as the Samuel Natelson Senior Investigator in recognition of outstanding service for the advancement of clinical chemistry and as the winner of the 1st Annual AI Free Memorial Lectureship.

Michael holds 60 allowed US patents and has 72 pending US patent applications yielding more than 500 worldwide patent filings. He also has more than 60 peer review publications, 15 book chapters and hundreds of conference papers and lectures in a wide variety of chemistry disciplines to his name. He earned his PhD in chemistry from Texas Tech University and his bachelor’s degree in chemistry from Clarkson University.

While working in industry, Michael has held pro-bono adjunct positions as a Visiting Scholar at the University of Notre Dame and as a Clinical Research Professor at the University of Louisville Medical School to pursue his research into the causes of inflammation during kidney disease and diabetes.


Highlights and Publications

  • Pugia, Michael & J Newman, David & A Lott, John & D'Mello, Lucia & Clark, Larry & A Profitt, James & Cast, Todd. (2003). Detection of low-molecular-weight proteins in urine by dipsticks. Clinica chimica acta; international journal of clinical chemistry. 326. 177-83. 10.1016/S0009-8981(02)00304-2. 
  • Pugia, Michael & Takemura, Toskihiho & Kuwajima, Shiro & Suzuki, Motoyohisa & K Cast, Todd & A Profit, James & S Schulman, Lloyd & Ohta, Yoshihide & A Lott, John. (2002). Clinical utility of a rapid test for uristatin. Clinical biochemistry. 35. 105-10. 10.1016/S0009-9120(02)00288-6.
  • A. Bartsch, Richard & L. Cowey, Charles & Elshani, Sadik & Goo, Mi-Ja & Huber, Vincent & N. Ivy, Sheryl & J. Johnson, Russell & Seung Kim, Jong & Luboch, Elzbieta & A. Mcdonough, Joseph & Pugia, Michael & Son, Byungki. (2001). Synthesis of lariat ether carboxylic acids based on dibenzo-16-crown-5. Journal of Heterocyclic Chemistry - J HETEROCYCL CHEM. 38. 311-331. 10.1002/jhet.5570380201.
  • Shihabi, Zak & P Schwartz, R & Pugia, Michael. (2001). Decreasing the variability observed in urine analysis. Annals of clinical and laboratory science. 31. 99-102. 

View All of Mike Pugia's Publications